Huiyue Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huiyue Qi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yingbo Dai
Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China
4 shared publications Deng Fei
Department of Urology, The Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha 410600, China
1 shared publication- Fei Deng
Department of Urology, The Second Xiangya Hospital at Central South University, Changsha, China
1 shared publication - Hao Qi
Department of Urology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China
1 shared publication - Hao Qi
Department of Urology, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China
1 shared publication - Hao Zhang
Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 9 January 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (4) , 541-564
Methylcrotonyl-CoA carboxylase 2 supports leucine catabolism to promote mitochondrial biogenesis and alleviate cisplatin-induced acute kidney injury
Cisplatin is widely used in clinical practice, but its nephrotoxicity severely limits its use. Previous studies have shown that cisplatin-induced acute kidney injury (AKI) is closely related to mitochondrial damage and that alleviating mitochondrial dysfunction can alleviate cisplatin-induced AKI. Methylcrotonyl‑CoA carboxylase 2 (MCCC2) is mainly located in mitochondria, where it catalyzes the catabolism of leucine and maintains mitochondrial function; however, the role of MCCC2 in cisplatin-induced renal injury has not yet been studied. In vitro, the expression of MCCC2 was manipulated by transfecting HK-2 cells with lentiviruses, and changes in the acetoacetate content, cell viability, apoptosis, oxidative stress, mitochondrial function, and mitochondrial biogenesis were evaluated. In vivo, MCCC2 overexpression was manipulated by adeno-associated viruses, and serum and kidneys were collected for subsequent experiments to detect changes in renal function, tissue damage, apoptosis, oxidative stress, mitochondrial damage, and mitochondrial biogenesis. We found that MCCC2 was downregulated in cisplatin-induced AKI models. In vitro, leucine catabolism was inhibited by cisplatin, while overexpression of MCCC2 supported leucine catabolism, upregulated peroxisome proliferator-activated receptor gamma coactivator 1-alpha expression, promoted mitochondrial biogenesis, improved mitochondrial function, and alleviated cisplatin-induced apoptosis and oxidative stress in HK-2 cells. In contrast, the knockdown of MCCC2 exacerbated these effects, while leucine deprivation reversed the effects of MCCC2 overexpression on mitochondrial function and biogenesis. In vivo, the overexpression of MCCC2 promoted mitochondrial biogenesis, maintained the integrity of the mitochondrial structure and function, and alleviated cisplatin-induced AKI. MCCC2 supported leucine catabolism and promoted mitochondrial biogenesis, providing a new therapeutic strategy for cisplatin-induced AKI.
- 9 January 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (4) , 541-564
Open AccessMethylcrotonyl-CoA carboxylase 2 supports leucine catabolism to promote mitochondrial biogenesis and alleviate cisplatin-induced acute kidney injury
Cisplatin is widely used in clinical practice, but its nephrotoxicity severely limits its use. Previous studies have shown that cisplatin-induced acute kidney injury (AKI) is closely related to mitochondrial damage and that alleviating mitochondrial dysfunction can alleviate cisplatin-induced AKI. Methylcrotonyl‑CoA carboxylase 2 (MCCC2) is mainly located in mitochondria, where it catalyzes the catabolism of leucine and maintains mitochondrial function; however, the role of MCCC2 in cisplatin-induced renal injury has not yet been studied. In vitro, the expression of MCCC2 was manipulated by transfecting HK-2 cells with lentiviruses, and changes in the acetoacetate content, cell viability, apoptosis, oxidative stress, mitochondrial function, and mitochondrial biogenesis were evaluated. In vivo, MCCC2 overexpression was manipulated by adeno-associated viruses, and serum and kidneys were collected for subsequent experiments to detect changes in renal function, tissue damage, apoptosis, oxidative stress, mitochondrial damage, and mitochondrial biogenesis. We found that MCCC2 was downregulated in cisplatin-induced AKI models. In vitro, leucine catabolism was inhibited by cisplatin, while overexpression of MCCC2 supported leucine catabolism, upregulated peroxisome proliferator-activated receptor gamma coactivator 1-alpha expression, promoted mitochondrial biogenesis, improved mitochondrial function, and alleviated cisplatin-induced apoptosis and oxidative stress in HK-2 cells. In contrast, the knockdown of MCCC2 exacerbated these effects, while leucine deprivation reversed the effects of MCCC2 overexpression on mitochondrial function and biogenesis. In vivo, the overexpression of MCCC2 promoted mitochondrial biogenesis, maintained the integrity of the mitochondrial structure and function, and alleviated cisplatin-induced AKI. MCCC2 supported leucine catabolism and promoted mitochondrial biogenesis, providing a new therapeutic strategy for cisplatin-induced AKI.
- Open Access
Myo-Inositol Supplementation Alleviates Cisplatin-Induced Acute Kidney Injury via Inhibition of Ferroptosis
Myo-inositol, a carbocyclic sugar, is believed to be relevant to renal pathobiology since the kidney is the major site for its catabolism. Its role in acute kidney injury (AKI) has not been fully investigated. Ferroptosis, a unique form of regulated cell death, is involved in various types of renal injuries. The relevance of myo-inositol with respect to the process of ferroptosis has not been explored either. Herein, our current exploratory studies revealed that supplementation of myo-inositol attenuates cisplatin-induced injury in cultured Boston University mouse proximal tubular (BUMPT) cells and renal tubules in vivo. Moreover, our studies unraveled that metabolic parameters pertaining to ferroptosis were disrupted in cisplatin-treated proximal tubular cells, which were seemingly remedied by the administration of myo-inositol. Mechanistically, we noted that cisplatin treatment led to the up-regulation of NOX4, a key enzyme relevant to ferroptosis, which was normalized by the administration of myo-inositol. Furthermore, we observed that changes in the NOX4 expression induced by cisplatin or myo-inositol were modulated by carboxy-terminus of Hsc70-interacting protein (CHIP), an E3 ubiquitin ligase. Taken together, our investigation suggests that myo-inositol promotes CHIP-mediated ubiquitination of NOX4 to decelerate the process of ferroptosis, leading to the amelioration of cisplatin-induced AKI.
Open AccessMyo-Inositol Supplementation Alleviates Cisplatin-Induced Acute Kidney Injury via Inhibition of Ferroptosis
Myo-inositol, a carbocyclic sugar, is believed to be relevant to renal pathobiology since the kidney is the major site for its catabolism. Its role in acute kidney injury (AKI) has not been fully investigated. Ferroptosis, a unique form of regulated cell death, is involved in various types of renal injuries. The relevance of myo-inositol with respect to the process of ferroptosis has not been explored either. Herein, our current exploratory studies revealed that supplementation of myo-inositol attenuates cisplatin-induced injury in cultured Boston University mouse proximal tubular (BUMPT) cells and renal tubules in vivo. Moreover, our studies unraveled that metabolic parameters pertaining to ferroptosis were disrupted in cisplatin-treated proximal tubular cells, which were seemingly remedied by the administration of myo-inositol. Mechanistically, we noted that cisplatin treatment led to the up-regulation of NOX4, a key enzyme relevant to ferroptosis, which was normalized by the administration of myo-inositol. Furthermore, we observed that changes in the NOX4 expression induced by cisplatin or myo-inositol were modulated by carboxy-terminus of Hsc70-interacting protein (CHIP), an E3 ubiquitin ligase. Taken together, our investigation suggests that myo-inositol promotes CHIP-mediated ubiquitination of NOX4 to decelerate the process of ferroptosis, leading to the amelioration of cisplatin-induced AKI.
- 6 November 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 3508-3512
A prediction method of NOx in thermal power plants using GC-LSTM neural network
The emission of NOx in thermal power plants would cause serious pollution to the environment, and effective prediction of NOx has important significance. With the development of deep learning, many methods can effectively solve the prediction problem. In this paper, a long short-term memory (LSTM) neural network based on the generalized correntropy (GC) loss function, which is called the GC-LSTM neural network here, is proposed to predict the NOx emission. In order to make the characteristics of high-dimensional data have the same measurement scale, normalization is used to preprocess data firstly. Then, the processed historical data is used as training data to train the GC-LSTM neural network. After that, the emission of the NOx at each time instant can be predicted according to the online measured relevant data based on the established GC-LSTM neural network. Finally, prediction results under the LSTM neural network with GC, mean square error (MSE) and the mean absolute error (MAE) loss functions are given. And according to the simulation results, it can be seen that the loss function curve of the LSTM network based on GC is more stable and has better convergence. It can be seen that the proposed GC-LSTM prediction is more accurate, by comparing the probability density function (PDF) and root mean square error (RMSE) of the error between the actual values and the prediction values.
- 6 November 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 3508-3512
A prediction method of NOx in thermal power plants using GC-LSTM neural network
The emission of NOx in thermal power plants would cause serious pollution to the environment, and effective prediction of NOx has important significance. With the development of deep learning, many methods can effectively solve the prediction problem. In this paper, a long short-term memory (LSTM) neural network based on the generalized correntropy (GC) loss function, which is called the GC-LSTM neural network here, is proposed to predict the NOx emission. In order to make the characteristics of high-dimensional data have the same measurement scale, normalization is used to preprocess data firstly. Then, the processed historical data is used as training data to train the GC-LSTM neural network. After that, the emission of the NOx at each time instant can be predicted according to the online measured relevant data based on the established GC-LSTM neural network. Finally, prediction results under the LSTM neural network with GC, mean square error (MSE) and the mean absolute error (MAE) loss functions are given. And according to the simulation results, it can be seen that the loss function curve of the LSTM network based on GC is more stable and has better convergence. It can be seen that the proposed GC-LSTM prediction is more accurate, by comparing the probability density function (PDF) and root mean square error (RMSE) of the error between the actual values and the prediction values.
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (2) , 421-431
Blockade of Adenosine A2b Receptor Reduces Tumor Growth and Migration in Renal Cell Carcinoma
Adenosine A2b receptor (A2bR) is a member of the G protein-coupled receptor superfamily members, which has been considered involved in the pathogenesis of various cancers. However, little is known about the role of A2bR renal cell carcinoma (RCC). The A2bR expression levels in RCC 769-P and Caki-1 cell lines compared with HK-2 were analyzed by qRT-PCR. 769-P and Caki-1 cells were transfected with shRNA-A2bR to knock down the expression of A2bR. Cell proliferation was detected by MTT assays and colony formation assays. Wounding healing assays and transwell assays were used to evaluate the effects of A2bR on cell capacity of invasion and migration. Finally, potential mechanisms involved in A2bR blockade's effects on altered tumor behaviors were evaluated by western blotting. We showed that A2bR were significantly up-regulated in RCC cells compared to HK-2 cell. Functionally, MRS1754, a selective A2bR antagonist, and knocking-down the expression of A2bR by shRNA reduced proliferation and migration in vitro and tumor growth in vivo. Furthermore, we demonstrated that A2bR blockade inhibited tumor progression in part via the MAPK/JNK pathway. Conclusion: Our findings suggest the A2bR potentially plays an important role in RCC progression and A2bR blockade may be a promising candidate for therapeutic intervention for renal cell carcinoma.
- 1 January 2020
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (2) , 421-431
Open AccessBlockade of Adenosine A2b Receptor Reduces Tumor Growth and Migration in Renal Cell Carcinoma
Adenosine A2b receptor (A2bR) is a member of the G protein-coupled receptor superfamily members, which has been considered involved in the pathogenesis of various cancers. However, little is known about the role of A2bR renal cell carcinoma (RCC). The A2bR expression levels in RCC 769-P and Caki-1 cell lines compared with HK-2 were analyzed by qRT-PCR. 769-P and Caki-1 cells were transfected with shRNA-A2bR to knock down the expression of A2bR. Cell proliferation was detected by MTT assays and colony formation assays. Wounding healing assays and transwell assays were used to evaluate the effects of A2bR on cell capacity of invasion and migration. Finally, potential mechanisms involved in A2bR blockade's effects on altered tumor behaviors were evaluated by western blotting. We showed that A2bR were significantly up-regulated in RCC cells compared to HK-2 cell. Functionally, MRS1754, a selective A2bR antagonist, and knocking-down the expression of A2bR by shRNA reduced proliferation and migration in vitro and tumor growth in vivo. Furthermore, we demonstrated that A2bR blockade inhibited tumor progression in part via the MAPK/JNK pathway. Conclusion: Our findings suggest the A2bR potentially plays an important role in RCC progression and A2bR blockade may be a promising candidate for therapeutic intervention for renal cell carcinoma.